The de-escalation of therapy helps avoid unnecessary toxicity from treatment in patients with brain cancer, explained Drs.

Colorectal cancer highlights from ASCO 2025 include findings from the BREAKWATER, ATOMIC, DYNAMIC-III, and TRIPLETE trials.

Targeted therapies and immunotherapy can provide benefits when added to chemotherapy or may eliminate the need for chemotherapy in certain patients with NSCLC.

ASCO 2025 delivered pivotal updates. In this article, we discuss 8 of the more interesting abstracts from an investment ...

This is the web version of STAT’s special newslette r from the annual meeting of the American Society of Oncology. For more ...

A version of this article first appeared in CNBC's Healthy Returns newsletter, which brings the latest health-care news ...

Treating patients with lung cancer always calls for a focus on informed and shared decision-making, according to expert ...

Dr Mariana Chavez MacGregor reports on advances from ASCO 2025, emphasizing treatment de-escalation and emerging tools like ctDNA for personalized care.

Breast cancer study results impressed at this year’s meeting, but raised new questions. Doctors also wrestled with how best ...

The FDA has already approved PARP inhibitors in certain patients with metastatic castration-resistant prostate cancer (mCRPC) ...

ASCO Data Shows New Therapy Extends Survival in Small Cell Lung Cancer. Here's what you need to know about the new ...

For patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast ...